Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Takashi KadowakiNobuya InagakiKazuoki KondoKenichi NishimuraGenki KanekoNobuko MaruyamaNobuhiro NakanishiHiroaki IijimaYumi WatanabeMaki GoudaPublished in: Diabetes, obesity & metabolism (2017)
Canagliflozin administered as add-on therapy to teneligliptin was effective and well tolerated in Japanese T2DM patients.